Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases

Area of Science:

• Immunology
• Cardiovascular Medicine
• Genomics & Proteomics

Background:

• Systemic autoimmune conditions (e.g., rheumatoid arthritis, lupus) are linked to increased atherosclerosis and cardiovascular disease (CVD) risk.
• Shared pathogenic mechanisms between autoimmune diseases and atherosclerosis are suggested by genomic and proteomic profiles in plaques.
• Auto-antibodies and deregulated protein expression in body fluids offer potential diagnostic markers for autoimmune-related CVD.

Purpose of the Study:

• To review novel genomic and proteomic approaches for assessing thrombotic risk in systemic autoimmune diseases.
• To explore the underlying mechanisms of vascular involvement in systemic autoimmune conditions.
• To highlight the importance of considering cardiovascular risk in managing patients with autoimmune disorders.

Main Methods:

• Analysis of genomic and proteomic data from atherosclerotic plaques.
• Identification of auto-antibodies in human sera and body fluids.
• Proteomic fingerprinting of blood cells, tissues, and body fluids to detect deregulated protein expression.

Main Results:

• Genomic and proteomic studies reveal shared profiles between atherosclerotic plaques and autoimmune diseases.
• Identification of auto-antibodies as potential diagnostic markers for specific autoimmune diseases.
• Proteomic analysis highlights deregulated protein expression patterns linked to vascular involvement.

Conclusions:

• Genomic and proteomic methods offer valuable insights into vascular complications of autoimmune diseases.
• Understanding these mechanisms is crucial for accurate thrombotic risk assessment.
• Integrated management of autoimmune disorders must prioritize cardiovascular health due to elevated CVD risk.